Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes

This study created a model to calculate the risks for developing blindness and end-stage renal disease for patients at different ages of diabetes onset and levels of glycemic control and addressed clinical risks and benefits associated with gly glucose control.

Abstract

This probability model, based on extrapolation from the experience with type 1 diabetes, suggests that patients with early onset of type 2 diabetes will accrue substantial benefit from almost-normal glycemic control. In patients with later onset, moderate glycemic control prevents most end-stage complications caused by microvascular disease. These results have important implications for informing patients and allocating health care resources.